Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Diabetes & metabolism（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要